Distinct outcomes in patients with different molecular subtypes of inflammatory breast cancer

Saudi Medical Journal

Volumn 35, Issue 11, 2014, Pages 1324-1330

  Zhou, Jingyu ^a   Yan, Yi ^a   Guo, Lei ^a   Ou, Huiying ^a   Hai, Jian ^a   Zhang, Chaojie ^b   Wu, Zhaoyun ^c   Tang, Lili ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Hunan Provincial People's Hospital   (China)

^c HUNAN CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN;

ADJUVANT THERAPY; ADULT; AGE; AGED; ANALYSIS OF VARIANCE; ARTICLE; BODY MASS; BREAST METASTASIS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CHI SQUARE TEST; CHINA; CLINICAL ARTICLE; CLINICAL FEATURE; DISTANT METASTASIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BREAST CANCER; KAPLAN MEIER METHOD; LACTATION; LARGE CORE NEEDLE BIOPSY; LYMPH NODE METASTASIS; MASTECTOMY; MENSTRUATION; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PATHOLOGY; PREGNANCY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; CARCINOMA; CLASSIFICATION; INFLAMMATORY BREAST NEOPLASMS; METABOLISM; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; KI-67 ANTIGEN; MASTECTOMY; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84910015034     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Levine PH, Veneroso C. The epidemiology of inflammatory breast cancer. Semin Oncol 2008; 35: 11-16.
2. Van Laere SJ, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, et al. Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct Afymetrix gene expression datasets. Clin Cancer Res 2013; 19: 4685-4696.
3. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Turlimann B, Senn HJ, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Terapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.
4. Shanbhogue AK, Karnad AB, Prasad SR. Tumor response evaluation in oncology: current update. J Comput Assist Tomogr 2010; 34: 479-484.
5. Brouckaert O, Laenen A, Vanderhaegen J, Wildiers H, Leunen K, Amant F, et al. Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. Ann Oncol 2012; 23: 2578-2584.
6. Falck AK, Bendahl PO, Chebil G, Olsson H, Ferno M, Ryden L. Biomarker expression and St Gallen molecular subtype classifcation in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years’ follow-up. Breast Cancer Res Treat 2013; 140: 93-104.
7. Chen FY, Ou HY, Wang SM, Wu YH, Yan GJ, Tang LL. Associations between body mass index and molecular subtypes as well as other clinical characteristics of breast cancer in Chinese women. Terapeutics and clinical risk management. Ter Clin Risk Manag 2013; 9: 131-137.
8. Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno N T, et al. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist 2011; 16: 1675-1683.
9. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010; 11: 174-183.
10. Gong P, Wang Y, Liu G, Zhang J, Wang Z. New insight into Ki67 expression at the invasive front in breast cancer. PLoS One 2013; 8: 54912.
11. Selz J, Stevens D, Jouanneau L, Labib A, Le Scodan R. Prognostic value of molecular subtypes, ki67 expression and impact of postmastectomy radiation therapy in breast cancer patients with negative lymph nodes after mastectomy. Int J Radiat Oncol Biol Phys 2012; 84: 1123-1132.
12. Song WJ, Kim KI, Park SH, Kwon MS, Lee TH, Park HK, et al. Te Risk Factors Infuencing between the Early and Late Recurrence in Systemic Recurrent Breast Cancer. J Breast Cancer 2012; 15: 218-223.
13. Goldhirsch A, Winer E P, Coates AS, Gelber RD, Piccart-Gebhart M, Turlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Terapy of Early Breast Cancer 2013. Ann Oncol 2013; 24: 2206-2223.
14. Panades M, Olivotto IA, Speers CH, Shenkier T, Olivotto TA, Weir L, et al. Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis. J Clin Oncol 2005; 23: 1941-1950.
15. Vermeulen PB, van Golen KL, Dirix LY. Angiogenesis, lymph angiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer: a review of the current knowledge. Cancer 2010; 116 (11 Suppl): S2748-S2754.
16. Ge X, Pan SM, Zeng F, Tang ZH, Wang Y W. A simple Chinese risk score model for screening cardiovascular autonomic neuropathy. PloS One 2014; 9: 89623.
17. Schairer C, Li Y, Frawley P, Graubard BI, Wellman RD, Buist DS, et al. Risk factors for inflammatory breast cancer and other invasive breast cancers. J Natl Cancer Inst 2013; 105: 1373-1384.
18. Edge SB, Compton CC. The American Joint Committee on Cancer: The 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann Surg Oncol 2010; 17: 1471-1474.
19. Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 2011; 22: 515-523.
20. Chen S, Chen CM, Yu KD, Zhou RJ, Shao ZM. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer. Ann Surg Oncol 2012; 19: 3002-3011.
21. Kasami M, Uematsu T, Honda M, Yabuzaki T, Sanuki J, Uchida Y, et al. Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy. Breast 2008; 17: 523-527.
22. Neubauer H, Gall C, Vogel U, Hornung R, Wallwiener D, Solomayer E, et al. Changes in tumour biological markers during primary systemic chemotherapy (PST). Anticancer Res 2008; 28: 1797-1804.